Skip to main content
Premium Trial:

Request an Annual Quote

10x Genomics Chromium System

10x Genomics has launched a new Chromium System, an upgrade for existing short-read sequencers. It unlocks critical long-range genomics and cell-by-cell gene expression information, the firm said. The system supports the following applications:

  • Chromium Single Cell 3', which performs deep profiling of complex cell populations with high-throughput digital gene expression on a cell-by-cell basis.
  • Chromium Genome, which provides long-range information on a genome-wide scale, enabling identification of critical variants in heritable disorders and discovery of key alterations in cancer.
  • Chromium Exome, which provides long-range information for phasing structural variant detection and copy number determination, giving researchers access to low-complexity and repetitive regions previously missed with short-read sequencing.
  • The Supernova Assembler, which opens the door to low-cost, everyday diploid de novo assemblies by unlocking sample-specific sequence and produces diploid genome structure.
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.